News of Pharmaceuticals | Healthcare | Wellness in Gujarat

Dr. Reddy’s Labs gets USFDA nod to market insomnia treatment drug

HYDERABAD | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Bourses, Hyderabad based Indian pharma major Dr. Reddy’s Laboratories Ltd said of having got US FDA (Food & Drugs Administration) nod to market drug to treat insomnia (troubles having to fall asleep). The press release submitted to the Indian Stock

Alembic Pharma gets USFDA nod to market drug to treat diabetis

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press release submitted to the Indian Bourses, Vadodara headquartered pharma major said of having got nod from US food and drug regulator to market drug to treat diabetis. The press release submitted by the comapany to the Indian Stock Exchanges read that, Alembic Pharmaceuticals

Laurus Labs’ exclusive distribution partner gets USFDA nod to market neuropathy treatment drugs

HYDERABAD | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Hyderabad headquartered Laurus Labs said of its exclusive distribution partner in US getting rights from US FDA (Food & Drugs Administration) to market neuropathy treatment drug. The press release submitted by the company to the Indian Bourses

Alembic Pharma gets USFDA nod to market neuropathic treatment drug

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Vadodara (Baroda) Gujarat based pharma major Alembic Pharmaceuticals Ltd said of having received nod from US FDA (Food & Drugs Administration) to market neuropathic & diabetic treatment drug. In the press release submitted to the Indian

Cipla’s subsidiary co gets USFDA nod to market neuropathy treatment drug

NEW YORK (USA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory filing submitted to the Indian Bourses, pharma major Cipla said of its subsidiary company InvaGen having got nod from US FDA (Food & Drugs Administration) to market neuropathy treatment drug. The press release submitted to the Indian Stock Exchanges read that Cipla’s

Zydus Cadila completes 3-phased clinical trial enrollment for drug, to cure liver disorder

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) said of having completed enrollment for three phase clinical trials of drug used to treat the a progressive disease of the liver – NASH. The press release submitted to the Indian

USFDA slams Form 483 to Torrent Pharma’s Dahej facility, official action initiated

DAHEJ | AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses late on Wednesday night, Ahmedabad headquartered pharma major Torrent Pharmaceuticals Ltd said of the company having classified as Official Action Initiated by US food & drugs regulator. The Dahej facility of the company was inspected in March 2019

JB Chem & Pharma inks pact for development of Navi Mumbai plots

MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update filed with Indian Bourses, Mumbai headquartered pharma company J. B. Chemicals & Pharmaceuticals Ltd said of having inked pact with developers for the company’s leasehold interest in plots of land at Navi Mumbai. Regulatory filing submitted by the company submitted to the Indian Stock Exchanges

Sun Pharma launches sprinkler version of lipid-lowering treatment

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Vadodara (Baroda) headquartered pharma Sun Pharmaceutical Industries Ltd said of having announced the sprinkler version for lipid-lowering treatment. The company has launched Ezallor Sprinkle™ (rosuvastatin) capsules in U.S. for the treatment of three types of elevated

Torrent Pharma inks diabetic drug marketing pact with Glenmark Pharma

AHMEDABAD | MUMBAI | RAJKOT –  In a press release submitted to the Indian Bourses by Glenmark Pharma it said that, Ahmedabad headquartered Torrent Pharmaceuticals and Glenmark Pharmaceuticals Ltd have inked agreement for co-marketing of diabetic treatment drug Remogliflozin Etabonate in India. The press release submitted to the Indian Exchanges on Thursday read that, Glenmark

SPARC submits cancer treatment drug for approval to USFDA

VADODARA (BARODA) | MUMBAI | AHMEDABAD – GANDHINAGAR | RAJKOT – In a press release issued to the Indian Stock Exchanges, Vadodara headquartered Sun Pharma Advanced Research Company (SPARC) Ltd said of having filed abbreviated new drug application (ANDA) for caner treatment to USFDA (US Food & Drugs Administration), which has been accepted by the

Alembic Pharma gets USFDA nod to market drug to treat epilepsy & seizures

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press release submitted to the Indian Stock Exchanges today, Vadodara (Baroda) headquartered Alembic Pharmaceuticals Ltd said of having received receives USFDA Approval for Clonazepam Orally Disintegrating Tablets USP, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg. The press release submitted by

Sun Pharma tie-ups with Chinese Pharma Co, to develop & commercialize Psoriasis treatment drug

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a press-release submitted to the stock exchanges in India, pharma major Sun Pharma said of entering into licensing agreement with a Chinese company for development and commercialization of treatment for psoriasis and psoriatic arthritis. The press release submitted to the Indian Bourses by the company

Torrent Pharma redeems 830 million rupees NCDs

AHMEDABAD-GANDHINGAR | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges on Tuesday, Ahmedabad headquartered pharma major Torrent Pharmaceuticals Ltd said of having redeemed 830 million rupees non-convertible debentures. The filing submitted by the company to the Exchanges read as narrated, Secured Redeemable Non-Convertible Debentures (NCDs) of ~ 83 crores (Rupees

Alembic Pharma gets USFDA nod to market drug to treat influenza

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR-RAJKOT – In a press release submitted to the Indian Bourses, Vadodara (Baroda) headquartered Alembic Pharmaceuticals Ltd said of having got approval from US Food & Drugs Administration (USFDA) to market drug to treat influenza. The press release submitted to the Indian Stock Exchanges read where the company said, Alembic

Biocon & Mylan to present final overall survival data of biosimilar for cancer

HERTFORDSHIRE (ENGLAND) | PITTSBURGH (US) | BENGALURU | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT  – In a press release submitted to the Exchanges in India on Thursday, Biocon Ltd said of Biocon and Mylan to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin4P, at the American Society of Clinical Oncology (ASCO) Annual